Oramed Pharmaceuticals Company Insiders
| ORMP Stock | USD 2.37 0.02 0.85% |
Slightly above 60% of all Oramed Pharmaceuticals' insiders are taking a long position. The analysis of insiders' sentiment of trading Oramed Pharmaceuticals stock suggests that some insiders are bullish at this time. Oramed Pharmaceuticals employs about 8 people. The company is managed by 8 executives with a total tenure of roughly 29 years, averaging almost 3.0 years of service per executive, having 1.0 employees per reported executive.
Oramed Pharmaceuticals' Insider Buying Vs Selling
60
Selling | Buying |
Latest Trades
| 2023-03-16 | Nadav Kidron | Acquired 26000 @ 2.04 | View | ||
| 2023-03-14 | Nadav Kidron | Acquired 100000 @ 2.01 | View | ||
| 2023-03-13 | Yadin Rozov | Acquired 20000 @ 1.96 | View | ||
| 2023-01-03 | Michael Rabinowitz | Disposed 13325 @ 12.55 | View | ||
| 2022-03-21 | Kevin Rakin | Disposed 10000 @ 9.41 | View |
Monitoring Oramed Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Oramed |
Oramed Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Oramed Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Oramed will maintain a workforce of slightly above 8 employees by January 2025.Oramed Pharmaceuticals' latest congressional trading
Congressional trading in companies like Oramed Pharmaceuticals, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Oramed Pharmaceuticals by those in governmental positions are based on the same information available to the general public.
| 2022-01-14 | Representative Andrew Garbarino | Acquired Under $15K | Verify |
Oramed Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.0412) % which means that it has lost $0.0412 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0289 %, meaning that it created $0.0289 on every $100 dollars invested by stockholders. Oramed Pharmaceuticals' management efficiency ratios could be used to measure how well Oramed Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Oramed Pharmaceuticals' Return On Tangible Assets are relatively stable compared to the past year. As of 12/01/2024, Return On Assets is likely to grow to 0.03, while Return On Capital Employed is likely to drop (0.1). At this time, Oramed Pharmaceuticals' Total Current Liabilities is relatively stable compared to the past year. As of 12/01/2024, Liabilities And Stockholders Equity is likely to grow to about 231.6 M, while Non Current Liabilities Total is likely to drop slightly above 4.2 M.As of 12/01/2024, Common Stock Shares Outstanding is likely to grow to about 42.6 M
Oramed Pharmaceuticals Workforce Comparison
Oramed Pharmaceuticals is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 2,413. Oramed Pharmaceuticals adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Oramed Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Oramed Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Oramed Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Oramed Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2023-03-01 | 1.3333 | 4 | 3 | 196,000 | 113,325 |
| 2022-09-01 | 3.6667 | 11 | 3 | 441,000 | 41,935 |
| 2022-03-01 | 2.8889 | 26 | 9 | 1,037,667 | 143,181 |
| 2021-09-01 | 1.1818 | 13 | 11 | 689,135 | 566,329 |
| 2021-03-01 | 5.0 | 5 | 1 | 355,000 | 78,125 |
| 2019-09-01 | 12.0 | 12 | 1 | 524,483 | 0.00 |
| 2019-06-01 | 1.5 | 3 | 2 | 63,146 | 43,146 |
| 2019-03-01 | 2.0 | 4 | 2 | 360,000 | 300,500 |
| 2018-09-01 | 3.0 | 3 | 1 | 2,622 | 61.00 |
| 2017-12-01 | 1.5 | 3 | 2 | 28,896 | 23,265 |
| 2017-09-01 | 0.5 | 3 | 6 | 213,511 | 238,012 |
| 2017-06-01 | 10.0 | 10 | 1 | 488,679 | 52,814 |
| 2015-12-01 | 1.0 | 7 | 7 | 294,724 | 342,459 |
| 2014-09-01 | 0.25 | 1 | 4 | 142,814 | 182,814 |
| 2014-06-01 | 4.5 | 9 | 2 | 286,896 | 274,600 |
| 2014-03-01 | 2.0 | 6 | 3 | 135,726 | 18,868 |
| 2012-12-01 | 4.5 | 9 | 2 | 7,738,088 | 4,836,852 |
| 2012-09-01 | 11.0 | 11 | 1 | 7,472,765 | 3,361,360 |
| 2007-12-01 | 2.0 | 2 | 1 | 95,000 | 0.00 |
Oramed Pharmaceuticals Notable Stakeholders
An Oramed Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Oramed Pharmaceuticals often face trade-offs trying to please all of them. Oramed Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Oramed Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Nadav Esq | CEO President | Profile | |
| Avraham Gabay | Treasurer CFO | Profile | |
| Joshua Hexter | COO and VP of Bus. Devel. | Profile | |
| Miriam Kidron | Chief Scientific Officer and Director | Profile | |
| Michael Rabinowitz | Chief Officer | Profile | |
| David CPA | CFO Treasurer | Profile | |
| Roy MD | Chief Board | Profile | |
| Netanel Derovan | Chief Secretary | Profile |
About Oramed Pharmaceuticals Management Performance
The success or failure of an entity such as Oramed Pharmaceuticals often depends on how effective the management is. Oramed Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Oramed management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Oramed management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.03 | 0.03 | |
| Return On Capital Employed | (0.09) | (0.10) | |
| Return On Assets | 0.03 | 0.03 | |
| Return On Equity | 0.03 | 0.04 |
Oramed Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Oramed Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Oramed Pharmaceuticals within its industry.Oramed Pharmaceuticals Manpower Efficiency
Return on Oramed Pharmaceuticals Manpower
| Revenue Per Employee | 167.5K | |
| Revenue Per Executive | 167.5K | |
| Net Income Per Employee | 636K | |
| Net Income Per Executive | 636K | |
| Working Capital Per Employee | 13.7M | |
| Working Capital Per Executive | 13.7M |
Additional Tools for Oramed Stock Analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.